Effect of Umbilical Cord Mesenchymal Stem Cells with/without Silymarin on Apoptosis, Immunomodulation, Proliferation, and Necrosis of HepG2 cells

Paulus Kusnanto, Bambang Purwanto, Brian Wasita, Vitri Widyaningsih

Abstract

Background: Liver cirrhosis and liver cancer are the main problems of liver disease, and liver cirrhosis is the 11th leading cause of death worldwide. Fibrosis is a progressive process of liver disease before cirrhosis. Currently, stem cells are designed to treat various conditions, including chronic liver disease. Stem cells can inhibit the progression of fibrosis based on their immunomodulation, anti-apoptotic and proliferative effects.  

Methods: This study was an in vitro experimental study. Mesenchymal stem cells (MSC) were taken from the umbilical cord of newborns. This study used the HepG2 cell line because it has the characteristics of Hepatocyte cells. Cell lines are made into four groups. The examination was performed on NF-κB, Caspase-3, Apoptosis, Necrosis, and Proliferation. 

Results: Mesenchymal stem cells have the effect of reducing NF-κB levels, increasing caspase 3 levels, reducing necrosis events, and increasing proliferation in HepG2 cells. Combining Mesenchymal stem cells with silymarin can increase caspase 3 levels and reduce the incidence of necrosis in HepG2 cells. 

Conclusion: Mesenchymal stem cells can regulate immunomodulation, increase proliferation, reduce necrosis, and regulate apoptosis of HepG2 cells.

Keywords

Mesenchymal stem cells, HepG2 cell line, Silymarin, Liver Fibrosis

Full Text:

PDF

References

1. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol [Internet]. 2019;70(1):151–71. Available from: https://doi.org/10.1016/j.jhep.2018.09.014

2. Cao Y, Ji C, Lu L. Mesenchymal stem cell therapy for liver fibrosis/cirrhosis. Ann Transl Med. 2020;8(8):562–562.

3. Zhang CY, Yuan WG, He P, Lei JH, Wang CX. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. World J Gastroenterol. 2016;22(48):10512–22.

4. Trautwein C, Friedman SL, Schuppan D, Pinzani M. Review Hepatic fibrosis : Concept to treatment. J Hepatol [Internet]. 2015;62(1):S15–24. Available from: http://dx.doi.org/10.1016/j.jhep.2015.02.039

5. Cheng JY-K, Wong GL-H. Advances in the diagnosis and treatment of liver fibrosis. Hepatoma Res. 2017;3(8):156.

6. Hmadcha A, Martin-Montalvo A, Gauthier BR, Soria B, Capilla-Gonzalez V. Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy. Front Bioeng Biotechnol. 2020;8(February):1–13.

7. Rodríguez-Fuentes DE, Fernández-Garza LE, Samia-Meza JA, Barrera-Barrera SA, Caplan AI, Barrera-Saldaña HA. Mesenchymal Stem Cells Current Clinical Applications: A Systematic Review. Arch Med Res. 2021;52(1):93–101.

8. Stefanska K, Ozegowska K, Hutchings greg, Popis M, Moncrieff L, Dompe C, et al. Human Wharton' s Jelly — Cellular Specificity , Stemness Potency , Animal Models , and Current Application in Human Clinical Trials. J Clin Med. 2020;9(1102):1–22.

9. Fong C-Y, Subramanian A, Biswas A, Bongso A. Freezing of Fresh Wharton0s Jelly From Human Umbilical Cords Yields High Post-Thaw Mesenchymal Stem Cell Numbers for Cell-Based Therapies. J Cell Biochem. 2016;827(September 2015):815–27.

10. Kobolak J, Dinnyes A, Memic A, Khademhosseini A, Mobasheri A. Mesenchymal stem cells: Identification, phenotypic characterization, biological properties and potential for regenerative medicine through biomaterial micro-engineering of their niche. Methods [Internet]. 2016;99(2016):62–8. Available from: http://dx.doi.org/10.1016/j.ymeth.2015.09.016

11. Shang Y, Guan H, Zhou F. Biological Characteristics of Umbilical Cord Mesenchymal Stem Cells and Its Therapeutic Potential for Hematological Disorders. Front Cell Dev Biol. 2021;9(May):1–11.

12. Song Z, Deaciuc I, Song M, Lee DY-W, Liu Y, Ji X, et al. Silymarin Protects Against Acute Ethanol-Induced Hepatotoxicity in Mice. Alcohol Clin Exp Res. 2006;30(3):407–13.

13. Abenavoli L, Capasso R, Milic N, Capasso F. Milk Thistle In Liver Disease : Past , Present , Future. Phyther Res. 2010;24(April):1423–32.

14. Gillessen A, Schmidt HHJ. Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review. Adv Ther [Internet]. 2020;37(4):1279–301. Available from: https://doi.org/10.1007/s12325-020-01251-y

15. Kim SH, Choo GS, Yoo ES, Woo JS, Han SH, Lee JH, et al. Silymarin induces inhibition of growth and apoptosis through modulation of the MAPK signaling pathway in AGS human gastric cancer cells. Oncol Rep. 2019;42(5):1904–14.

16. Ou Q, Weng Y, Wang S, Zhao Y, Zhang F, Zhou J, et al. Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the Nf-κB Pathway. Dig Dis Sci [Internet]. 2018;63(12):3398–408. Available from: https://doi.org/10.1007/s10620-018-5268-0

17. Mustika S, Pratomo B, Achmad H, Ohyho D, Irxqg ZD V, Wkh LQ, et al. Comparing the Effects of Genistein , Silymarin , Lecithin on Improved Liver Necrosis Induced by Paracetamol Toxic Dose Administration in Rattus novergicus Wistar Strain. Indones J Gastroenterol Hepatol Dig Endosc. 2012;13(1):29–36.

18. Schu S, Nosov M, O'Flynn L, Shaw G, Treacy O, Barry F, et al. Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med. 2012;16(9):2094–103.

19. Tsuchiya A, Takeuchi S, Watanabe T, Yoshida T, Nojiri S, Ogawa M, et al. Mesenchymal stem cell therapies for liver cirrhosis: MSCs as "conducting cells" for improvement of liver fibrosis and regeneration. Inflamm Regen. 2019;39(1):4–9.

20. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini FC, Krause DS, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy [Internet]. 2006;8(4):315–7. Available from: http://dx.doi.org/10.1080/14653240600855905

21. Wu MC, Meng QH. Current understanding of mesenchymal stem cells in liver diseases. World J Stem Cells. 2021;13(9):1349–59.

22. Du Z, Wei C, Cheng K, Han B, Yan J, Zhang M, et al. Mesenchymal stem cell-conditioned medium reduces liver injury and enhances regeneration in reduced-size rat liver transplantation. J Surg Res [Internet]. 2013;183(2):907–15. Available from: http://dx.doi.org/10.1016/j.jss.2013.02.009

23. Sun H, Shi C, Ye Z, Yao B, Li C, Wang X, et al. The role of mesenchymal stem cells in liver injury. Cell Biol Int. 2022;46(4):501–11.

24. Lin N, Hu K, Chen S, Xie S, Tang Z, Lin J, et al. Nerve growth factor-mediated paracrine regulation of hepatic stellate cells by multipotent mesenchymal stromal cells. Life Sci [Internet]. 2009;85(7–8):291–5. Available from: http://dx.doi.org/10.1016/j.lfs.2009.06.007

25. Wang P, Xie D, Liang X, Peng L, Zhang G, Ye Y, et al. HGF and Direct Mesenchymal Stem Cells Contact Synergize to Inhibit Hepatic Stellate Cells Activation through TLR4 / NF-kB Pathway. PLoS One. 2012;7(8):1–13.

26. Yu F, Ji S, Su L, Wan L, Zhang S, Dai C, et al. Adipose-derived mesenchymal stem cells inhibit activation of hepatic stellate cells in vitro and ameliorate rat liver fibrosis in vivo. J Formos Med Assoc [Internet]. 2013;xx:1–9. Available from: http://dx.doi.org/10.1016/j.jfma.2012.12.002

27. Lee C, Kim M, Han J, Yoon M, Jung Y. Mesenchymal stem cells influence activation of hepatic stellate cells, and constitute a promising therapy for liver fibrosis. Biomedicines. 2021;9(11).

28. Howley B, Fearnhead HO. Caspases as therapeutic targets. J Cell Mol Med. 2008;12(5):1502–16.

29. Thapaliya S, Wree A, Povero D, Inzaugarat ME, Berk M, Dixon L, et al. Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model. Dig Dis Sci. 2014;59(6):1197–206.

30. Shokravi S, Borisov V, Zaman BA, Niazvand F, Hazrati R. Mesenchymal stromal cells ( MSCs ) and their exosome in acute liver failure ( ALF ): a comprehensive review. Stem Cell Res Ther [Internet]. 2022;13(192):1–21. Available from: https://doi.org/10.1186/s13287-022-02825-z

31. Lee UE, Friedman SL. Mechanisms of Hepatic Fibrogenesis. Best Pr Res Clin Gastroenterol. 2012;25(2):1–15.

32. Nazarie SR, Gharbia S, Hermenean A, Dinescu S, Costache M. Regenerative potential of mesenchymal stem cells' (MSCs) secretome for liver fibrosis therapies. Int J Mol Sci. 2021;22(24).

33. Zhou Q, Rong C, Gu T, Li H, Wu L, Zhuansun X, et al. Mesenchymal stem cells improve liver fibrosis and protect hepatocytes by promoting microRNA-148a-5p-mediated inhibition of Notch signaling pathway. Stem Cell Res Ther [Internet]. 2022;13(1):1–17. Available from: https://doi.org/10.1186/s13287-022-03030-8

34. Krishna M. Patterns of necrosis in liver disease. Clin Liver Dis. 2017;10(2):53–6.

35. Wu L, Zhang Q, Mo W, Feng J, Li S, Li J, et al. Quercetin prevents hepatic fibrosis by inhibiting hepatic stellate cell activation and reducing autophagy via the TGF-β1/Smads and PI3K/Akt pathways. Sci Rep [Internet]. 2017;7(1):1–13. Available from: http://dx.doi.org/10.1038/s41598-017-09673-5

DOI: https://doi.org/10.20961/tscm.v1i2.80110

Refbacks

  • There are currently no refbacks.